Foresight or folly? Generics firms' foray into NCEs

Foresight or folly? Generics firms’ foray into NCEs
A number of generics firms have, over the last few years, veered off the path and started to develop innovative drugs in their own right. In a time when generics firms are showing the greatest growth in the pharmaceutical sector, what has driven them to venture into new territory?

Comments are closed.

Do NOT follow this link or you will be banned from the site!